Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialDaniel D. Mikol, Bernard M.J. Uitdehaag, Frederik Barkhof et al.|The Lancet Neurology|2008Cited by 484
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O’Connor, Timon Bogumil, Massimo Filippi et al.|The Lancet Neurology|2009Cited by 403
Placebo-Controlled Trial of Oral Laquinimod for Multiple SclerosisGıancarlo Comı, Massimo Filippi, Douglas Jeffery et al.|New England Journal of Medicine|2012Cited by 362
Devic's neuromyelitis optica: A clinicopathological study of 8 patientsRaúl N. Mandler, Mario Kornfeld, Larry E. Davis et al.|Annals of Neurology|1993Cited by 335
MS disease activity in RESTORERobert J. Fox, Petra W. Duda, Bianca Weinstock‐Guttman et al.|Neurology|2014Cited by 192